Brain Ischemia – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Brain Ischemia Market Outlook

Thelansis’s “Brain Ischemia Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Brain Ischemia treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Brain Ischemia Overview

Brain ischemia may manifest as localized or widespread. Shock is one of the common systemic mechanisms that lead to global cerebral ischemia. Systemic hypotension is the most common cause of global cerebral ischemia. When autonomic and neurohormonal systems that regulate blood pressure and heart rate are compromised, as they are in postural tachycardia syndromes and vasovagal syncope, hypoperfusion can result. When an artery supplying a portion of the brain suddenly closes or significantly narrows, it can result in localized or multifocal cerebral ischemia. When hemodynamic dysfunction is the more immediate cause of a sharp drop in blood pressure, brain ischemia is often caused by a loss of blood supply to the entire brain. Usually, treating global brain ischemia aims to address the underlying cause. Supportive care should be implemented to guarantee sufficient cerebral blood flow; this can be achieved by keeping the patient flat or in the Trendelenburg position while further supportive measures are implemented. Assessing the patient's eligibility for acute reperfusion therapy is the first step in treating an acute ischemic stroke. For almost 25 years, intravenous thrombolytics have been used to treat acute ischemic stroke. As of right now, the only thrombolytic drug that the Food and Drug Administration has approved for the treatment of acute ischemic stroke, while tenecteplase efficacy research is ongoing. TPA has been approved for the treatment of acute ischemic stroke, provided it is given within three hours of the onset of symptoms; however, research suggests that giving TPA up to four hours after the onset of symptoms may still be safe and beneficial.

• In the US, the incidence rises with age; those over 65 account for roughly 75% of cases. Over the past 15 years, the prevalence of stroke has dropped in men, but it is almost the same in women, with a little female predominance.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2023-2033

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: